¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ehrlich ascites tumor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® medullary tumor ÇÑ±Û ¼öÁú¼º Á¾¾ç
¼³¸í   
  ¾ÏÀÇ º´¸®ÇÐÀûÀΠºÐ·ùÁß Çϳª. ¿©·¯ ±â°üÀÇ ¾Ï¿¡¼­ ³ªÅ¸³ª´Âµ¥ ÁַΠ°©»ó»ù¾ÏÀ̳ª À¯¹æ¾Ï¿¡¼­ º¸ÀδÙ.
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
¿µ¹® benign tumor ÇÑ±Û ¾ç¼ºÁ¾¾ç
¼³¸í   
  ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, Ä§À±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇϴ Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀΠ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í Çصµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇϴ ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡Çϴ ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇϴ ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸À̴ Á¾¾çµµ ÀÖ´Ù.
¿µ¹® Wilms' tumor ÇÑ±Û Àª¸§ÁîÁ¾¾ç
¼³¸í   
  ÄáÆÏ¿¡¼­ ¹ß»ýÇϴ ¾Ç¼ºÁ¾¾çÀ¸·Î ¼Ò¾Æ¿¡¼­ ÀÚÁÖ ¹ß»ýÇÑ´Ù. ÈçÈ÷ ¼Ò¾Æ¿¡¼­ º¹ºÎ³»Á¾¾çÀ» ¹ß°ß½Ã Áß¾Ó¼±À» ³Ñ¾î¼­¸é ½Å°æ¸ð¼¼Æ÷Á¾À̰í, Áß¾Ó¼±À» ³ÑÁö ¾ÊÀ¸¸é Àª¸§ÁîÁ¾¾çÀ» ÀǽÉÇÒ ¸¸Å­ Áß¿äÇϰí ÈçÇÑ Á¾¾çÀÌ´Ù. ´ë°³ Áõ»óÀº ¾ø´Â ÆíÀ̸ç, ÁַΠ¾Æ±âÀÇ ¸ñ¿åÀ» ½ÃÄÑÁÖ´Ù°¡ ¿ì¿¬È÷ ¹ß°ßµÈ º¹ºÎ³»Á¾±« ¶§¹®¿¡ º´¿øÀ» Ã£°Ô µÈ´Ù. Áø´Ü½Ã ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µÀ¸·Î ÁÖÀ§ÀÇ ÀüÀ̰¡ ¾ø´ÂÁö¸¦ È®ÀÎÇØ¾ß Çϸç, ÀüÀ̰¡ ¾øÀ¸¸é Ç×¾ÏÈ­Çпä¹ý, ¹æ»ç¼±Ä¡·á¿ä¹ý, ±×¸®°í ¼ö¼ú¿ä¹ýÀÇ º´ÇÕ¿ä¹ý¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù. 
¿µ¹® mucinous tumor ÇÑ±Û Á¡¾×Á¾¾ç
¼³¸í   
  Á¡¾×À¸·Î ±¸¼ºµÈ Á¾¾çÀ» ¸»Çϴµ¥ ÁַΠ¿©¼ºÀÇ ³­¼Ò¿¡¼­ ¹ß»ýÇϴ ³¶¼º(¹°ÁָӴϰ°Àº Á¾¾çÀ» ¸»ÇÔ) Á¾¾ç¿¡¼­ ¸¹ÀÌ º¼ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç, ³»¹è¿±µ¿Á¾¾ç
  • fecal tumor
    ´ëº¯µ¢ÀÌ, ºÐÁ¾(ÝÐðþ)
  • gastrointestinal autonomic nerve tumor
    À§Ã¢ÀÚÀÚÀ²½Å°æÁ¾¾ç, À§Àå°üÀÚÀ²½Å°æÁ¾¾ç
  • gastrointestinal stromal tumor
    À§Ã¢ÀÚ±âÁúÁ¾¾ç, À§Àå°ü±âÁúÁ¾¾ç
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç
  • Gleason tumor grade
    ±Û¸®½¼Á¾¾çµî±Þ
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa-theca cell tumor
    °ú¸³³­Æ÷¸·¼¼Æ÷Á¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
  • juxtaglomerular cell tumor
    Å丮°ç¼¼Æ÷Á¾¾ç, »ç±¸Ã¼¿·¼¼Æ÷Á¾¾ç
  • Krukenberg¡¯s tumor
    Å©·çÄ˹ö±×Á¾¾ç
  • Leydig cell tumor
    ¶óÀ̵ðÈ÷¼¼Æ÷Á¾¾ç
  • mixed germ cell tumor
    È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • occult primary tumor
    Àẹ¿ø¹ßÁ¾¾ç
  • odontogenic tumor
    Ä¡¾ÆÅ¿Á¾¾ç, Ä¡¿øÁ¾¾ç
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç, ·¹´ÑºÐºñ»ç±¸Ã¼¿·Á¾¾ç
  • Sertoli-Leydig tumor
    ¼¼¸£Å縮¶óÀ̵ðÈ÷ Á¾¾ç
  • smooth muscle tumor
    ÆòȰ±ÙÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • tumor control
    Á¾¾ç¾ïÁ¦
  • tumor lymphnode metastasis classification
    Á¾¾ç¸²ÇÁÀýÀüÀ̺зù
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • tumor embolism
    Á¾¾ç»öÀüÁõ
  • fecal tumor
    (¢¡stercoroma) ´ëº¯µ¢ÀÌ
  • tumor angiogenesis factor
    Á¾¾çÇ÷°üÇü¼ºÀÎÀÚ
  • tumor necrosis factor
    Á¾¾ç±«»çÀÎÀÚ
  • genitourinary tumor
    ºñ´¢»ý½ÄÁ¾¾ç
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • gross tumor volume
    ¸Ç´«Á¾¾çüÀû
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • heterogenous tumor
    ÀÌÁúÁ¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acoustic tumor
    û½Å°æÁ¾¾ç
  • adenomatoid tumor
    ¼±¾çÁ¾¾ç
  • adenomatoid tumor
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), À¯¼±Á¾Á¾¾ç(×¾àÍðþðþåË)
  • adenomatoid tumor, tubal
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), ³­°ü(Ñëη)ÀÇ
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal rest tumor
    ºÎ½ÅÀÜÀ¯Á¾¾ç
  • adrenal tumor
    ºÎ½ÅÁ¾¾ç(ÜùãìðþåË).
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • amyloid tumor
    ¾Æ¹Ð·ÎÀ̵åÁ¾¾ç.
  • angiomatoid tumor
    À¯Ç÷°üÁ¾ Á¾¾ç, Ç÷°üÁ¾¾ç Á¾¾ç
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • appendigeal tumor
    ºÎ¼Ó±â Á¾¾ç(ðþåË)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hydrogaster =ascites
    º¹¼ö(º¹¼ö).
  • hydrogaster =ascites
    º¹¼ö(ÜÙâ©).
  • hydrops abdominis =ascites
    º¹¼ö(º¹¼ö).
  • hydrops abdominis =ascites
    º¹¼ö(ÜÙâ©).
  • pancreatic ascites
    ÃéÀ强º¹¼ö.
  • seroperitoneum =ascites
    º¹¼ö(ÜÙâ©).
  • seroperitoneum =ascites
    º¹¼ö(ÜÙâ©)
  • transudative ascites
    ´©Ã⼺ º¹¼ö(שõóàõ ÜÙâ©)
  • tuberculous ascites
    °áÇÙ¼º º¹¼ö(°áÇÙ¼ºº¹¼ö).
  • brain tumor =cerebral tumor
    ½Å ¿Ü ³úÁ¾¾ç(ÒàðþåË).
  • superior sulcus tumor(carcinoma)=pancoast tumor
    »ó±¸¾ÏÁ¾
  • trichilemmal tumor => pilar tumor
  • tumor albus =white tumor ³ª
    ¹éÁ¾(ÛÜðþ)
  • acinic cell tumor
    ¼±¹æ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • acoustic tumor
    û½Å°æÁ¾¾ç
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mucoepidermoid tumor
    Á¡¾×Ç¥ÇǾçÁ¾¾ç
  • mucous tumor
    Á¡¾×Á¾
  • nasopharyngeal tumor
    ºñÀεÎÁ¾¾ç
  • neurogenic tumor
    ½Å°æ(¿ø)¼ºÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´É¼ºÁ¾¾ç
  • odontogenic tumor
    Ä¡(¿ø)¼ºÁ¾¾ç
  • ovarian tumor
    ³­¼ÒÁ¾¾ç
  • papillary tumor
    À¯µÎ»ó Á¾¾ç
  • phantom tumor
    ȯ»óÁ¾¾ç
  • primary tumor
    ¿ù¹ßÁ¾¾ç
  • solid tumor
    Ãæ½Ç¼ºÁ¾¾ç
  • superior sulcus tumor
    »ó±¸Á¾¾ç
  • supratentorial tumor
    õ¸·»óÁ¾¾ç
  • teratodermoid tumor
    ±âÇüÀ¯ÇÇÁ¾
  • teratoid tumor
    ±âÇü¾çÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
BT base of tongue; bedtime; bitemporal; bitrochanteric; bladder tumor; Blalock-Taussig [shunt]; bleedin...
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
TNM primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas...
AH abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ATLS Acute tumor lysis syndrome
AOT Adenomatoid odontogenic tumor
TNF Anti-tumor necrosis factor
anti-TNF alpha Anti-tumor necrosis factor alpha
BTA Bladder tumor antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • bladder tumor
    ¹æ±¤ Á¾¾ç
    ¹æ±¤ º®ÀÇ °¢ Á¶Á÷¿¡ ¹ß»ýÇÏ´Â Á¾¾ç. À¯µÎÁ¾, ¼±Á¾, ±ÙÁ¾, ÇǺξçÁ¾, Áö¹æÁ¾, Ç÷°üÁ¾ µî ¾ç¼ºÀÎ °Í°ú ¾Ï, À°Á¾ µî ¾Ç¼ºÀÎ °ÍÀÌ ÀÖÀ¸¸ç, ¾à 10 %¸¸ÀÌ ¾ç¼ºÀÌ°í ´ëºÎºÐÀÌ ¾Ç¼ºÀ¸·Î ¹ß»ý ¿øÀÎÀº ºÒ¸íÀÌ´Ù. ƯÁ¤ ±âÈ£ À½·á³ª ¾à¹°ÀÇ Àå±â ¿¬¿ë µî¿¡ ÀÇÇÏ´Â °Í°ú ¾Æ´Ò¸°°è ¾àǰÀ» Ãë±ÞÇÏ´Â °øÀå ±Ù·ÎÀÚ¿¡°Ô¼­ º¸°Ô µÇ´Â Á÷¾÷ ¾ÏÀÌ ÁÖ¸ñµÇ°í ÀÖ´Ù. ¶ÇÇÑ ¹æ±¤ Á¾¾çÀº Áß³â ÀÌÈÄ¿¡ Àß ¹ß»ýµÇ¸ç ¿©ÀÚº¸´Ù ³²ÀÚ¿¡°Ô ¸¹´Ù. Ãʱâ Áõ¼¼´Â Ç÷´¢¸¦ º¸ÀÌ´Ù°¡ ÀúÀý·Î ¸ÜÀ¸¸ç, ÀÌ·± ÀÏÀÌ ¹Ýº¹µÇ´Â µ¿¾È¿¡ ¹æ±¤¿°, ½Å¿ì½Å¿°À» º´¹ßÇÏ¿© ¹è´¢Åë, ºó´¢, Ç÷³ó´¢¿Í ¿äÅëÀÌ ³ªÅ¸³­´Ù. ¶§·Î´Â ¹æ±¤ ¾È¿¡ ÀÀÇ÷ÀÌ »ý±â°í ¹æ±¤ Ãⱸ¿¡ Á¾¾çÀÌ »ý°Ü ¹è´¢ Àå¾Ö°¡ ¿À±âµµ ÇÑ´Ù. ¹æ±¤°æ °Ë»ç·Î Áø´ÜÇϸç, ħÀ±¼ºÀÌ °­ÇϹǷΠÁ¶±â Áø´Ü ¹× Á¶±â Ä¡·á°¡ ¹Ù¶÷Á÷ÇÏ´Ù. Ä¡·á¹ýÀ¸·Î´Â ¿©·¯ °¡Áö ºñ´¢±â°úÀû ¼ö¼ú¹ý°ú ¹æ»ç¼± ¿ä¹ýÀÌ ÀÖÀ¸¸ç, Á¾¾çÀÇ ¼º»ó°ú ȯÀÚÀÇ ¿¬·É ¹× Àü½Å »óÅ µî¿¡ µû¶ó¼­ ÀÌ µÎ °¡Áö¸¦ Àû´çÈ÷ ¼¯¾î Ä¡·áÇÏ´Â Ä¡·á¹ýÀ» »ç¿ëÇÑ´Ù. ¾Ç¼ºÀÎ °æ¿ì ¹æÄ¡Çϸé ÇÒ¼ö·Ï ¹æ±¤ÀÇ ÁÖº¯ ¹× ¸Ö¸® ¶³¾îÁø ºÎÀ§¿¡µµ ÀüÀÌÇÏ¿© Ä¡À¯µÇ±â ¾î·Á¿öÁø´Ù. Àç¹ßÇϱ⠽¬¿î ÁúȯÀ̹ǷΠġ·á ÈÄ¿¡µµ 1³â¿¡ 3ȸ Á¤µµ ¹Ý¿µ±¸ÀûÀ¸·Î Á¤±â °ËÁøÀ» ¹Þ¾Æ¾ß Çϸç, Ç÷´¢°¡ ³ªÅ¸³ª¸é Áï½Ã ÁøÂûÀ» ¹Þµµ·Ï ÇÑ´Ù.
  • bluish tumor
    Ǫ¸¥ »ö Á¾¾ç
  • bone tumor
    °ñ Á¾¾ç
    óÀ½¿¡ »À¿¡ ¹ß»ýÇÏ´Â Á¾¾ç. ´Ù¸¥ ºÎÀ§¿¡¼­ ¾ÏÀÌ ÀüÀÌÇÏ´Â Àϵµ ÀÖÀ¸³ª, ´ëºÎºÐÀº Á¶°ñ¼¼Æ÷³ª Á¶Á÷ÀÇ ÀÌ»ó Áõ½Ä¿¡ ÀÇÇÏ¿© »ý±ä´Ù. °ñ Á¶Á÷ ÀÚü¿¡¼­ ¹ß»ýÇÏ´Â Á¾¾çÀ¸·Î´Â °ñÁ¾, ¿¬°ñÁ¾ÀÌ ÀÖ°í, »À¿¡ Æ÷ÇÔµÈ °áÇÕÁ¶Á÷¿¡¼­ ¹ß»ýÇÏ´Â ¼¶À¯Á¾, Ç÷°ü¿¡¼­ ¹ß»ýÇÏ´Â Ç÷°üÁ¾, °ñ¼ö¿¡¼­ ¹ß»ýÇÏ´Â °ñ¼öÁ¾ÀÌ ÀÖ´Ù. °ñ¼öÁ¾À» Á¦¿ÜÇϰí´Â ¸ðµÎ ¾ç¼º Á¾¾çÀ¸·Î »ý¸íÀÇ À§ÇèÀÌ µû¸£´Â ÀÏÀº ¾ø°í °ÅÀÇ Å¸°¢ ¼Ò°ß
  • brenner tumor
    ºê·»³Ê Á¾¾ç
    µå¹® ³­¼Ò Á¾¾çÀÌ´Ù. ¾î¸°ÀÌ¿¡¼­ ³ëÀαîÁö ¸ðµç ¿¬·É¿¡ ¹ß»ýµÇ³ª ´ëºÎºÐÀÌ 50¼¼ ÀÌÈÄ¿¡ »ý±ä´Ù. À°¾ÈÀûÀ¸·Î ´ëºÎºÐ °íÇü¼ºÀÌ°í ´Ü´ÜÇÏ¸ç ¼è¹é»öÀ̳ª µå¹°°Ô ÀÛÀº ³¶¼º ºÎÀ§°¡ Àְųª ¿ÏÀüÇÑ ³¶¼ºÀÏ ¼öµµ ÀÖ´Ù. Å©±â´Â 1cm ¹Ì¸¸ÀÇ ÀÛÀº Á¾¾ç¿¡¼­ ¸Å¿ì Å« Á¾¾ç±îÁö ´Ù¾çÇÏÁö¸¸ ´ë°³´Â Á÷°æ 2-8cmÀÌ´Ù. Çö¹Ì°æÀûÀ¸·Î »óÇÇ ¼¼Æ÷¿Í °£Áú ¼¼Æ÷·Î ±¸¼ºµÇ¾î ÀÖ°í »óÇÇ ¼¼Æ÷´Â ¾ãÀº È£»ê¼º ¼¼Æ÷Áú°ú Ÿ¿øÇü ¼¼Æ÷ÇÙÀ» °®´Âµ¥ Ư¡ÀûÀÎ ¼¼Æ÷ÇÙÀÇ "±¸" Áï "Ä¿ÇÇ ¾Ë" ¸ð¾çÀ» ÇÏ°Ô µÈ´Ù. °£Áú ¼¼Æ÷´Â ³­Æ÷¸· ¼¼Æ÷¸¦ ´à±âµµ ÇÑ´Ù. ´Ù¸¥ Á¾¾ç ƯÈ÷ Á¡¾×¼º ³¶¼±Á¾À̳ª ³¶¼º ±âÇüÁ¾°ú ÇÔ²² ¹ß»ýÇÏ´Â °ÍÀÌ Àß ¾Ë·ÁÁ® ÀÖ´Ù.
  • broad based tumor
    ±âÀúºÎ°¡ ³ÐÀº Á¾¾ç
  • calcified epithelial odontogenic tumor
    ¼®È¸È­ »óÇǼº Ä¡¼º Á¾¾ç
  • carotid body tumor
    °æµ¿¸Æ ¼Òü Á¾¾ç
  • cartilaginous tumor
    ¿¬°ñ¼º Á¾¾ç
    Á¶ÀýÇÒ ¼ö ¾øÀ» Á¤µµ·Î °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿­¿¡ ÀÇÇÑ ¿¬°ñ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë.
  • cavernous tumor
    ÇØ¸é»ó Á¾¾ç, ÇØ¸éÁ¾
    µ¿ÀǾî=cavenoma.
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
  • cerebellopontine tumor
    ¼Ò³ú ±³°¢ Á¾¾ç
  • children tumor
    ¼Ò¾Æ ¾Ï
    ¼Ò¾Æ¿¡°Ô »ý±â´Â ¾Ç¼º Á¾¾ç. ¼Ò¾Æ¿¡°Ô´Â À§¾Ï, Æó¾Ï, Àڱà ¾Ï µîÀº °ÅÀÇ º¼ ¼ö ¾øÁö¸¸, ±Þ¼º ¹éÇ÷º´, ¾Ç¼º ¸²ÇÁÁ¾, ³úÁ¾¾ç, °íȯ žƼº ¾Ï, ½Å°æ¾Æ¼¼Æ÷Á¾, °£¾Ï, °ñ À°Á¾, ºñ·ç½º¼º Á¾¾ç µîÀÌ ¸¹´Ù.
  • congenital intracranial tumor
    ¼±Ãµ¼º µÎ°³³» Á¾¾ç
  • delta cell tumor
    µ¨Å¸ ¼¼Æ÷ Á¾¾ç
    ¼Ò¸¶Å佺ŸƾÀ» ºÐºñÇÏ´Â Á¾¾çÀ¸·Î ¼Ò¸¶Å佺ŸƾÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Paul Ehrlich <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology.
Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series.
In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background.
Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units).
at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced.
Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy.
In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915.
Lived: 1854-1915.
(18 Nov 1997)
Heinz-Ehrlich body A round oxyphil body found in the red blood cell in case of haemocytolysis due to a specific blood poison.
Synonym: Heinz-Ehrlich body.
(05 Mar 2000)
Ehrlich Paul, German bacteriologist, immunologist, and Nobel laureate, 1854-1915.
See: Ehrlichia, Ehrlich's anaemia, Ehrlich's inner body, Ehrlich's phenomenon, Ehrlich's postulate, Ehrlich's diazo reagent, Ehrlich's theory, Ehrlich-Turk line. See entries under stain; reaction.
(05 Mar 2000)
Ehrlich, Paul <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology.
Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series.
In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background.
Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units).
at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced.
Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy.
In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915.
Lived: 1854-1915.
(18 Nov 1997)
Ehrlich reaction The reaction of the indole derivatives with aromatic aldehydes; e.g., tryptophan and p-dimethylaminobenzaldehyde in H2SO4 give a red-violet colour useful in assaying proteins for tryptophan content.
Synonym: Ehrlich reaction.
(05 Mar 2000)
Ehrlich's acid haematoxylin stain <technique> An alum type of haematoxylin stain used as a regressive staining method for nuclei, followed by differentiation to required staining intensity; the solution may be allowed to ripen naturally in sunlight or partially oxidised with sodium iodate.
(05 Mar 2000)
Ehrlich's anaemia <haematology> This form of anaemia occurs when the bone marrow ceases sufficient red and white blood cell production. It may be induced by exposures to high levels of toxic chemicals, radiation and certain drugs.
It is generally unresponsive to specific therapy, often accompanied by granulocytopenia and thrombocytopenia, in which the bone marrow may not necessarily be hypocellular or hypoplastic but fails to produce adequate numbers of peripheral blood elements. The term actually is all inclusive and most probably encompasses several clinical syndromes.
Origin: Gr. Haima = blood
(29 Sep 1997)
Ehrlich's aniline crystal violet stain <technique> A stain for Gram-positive bacteria.
(05 Mar 2000)
Ehrlich's benzaldehyde reaction A test for urobilinogen in the urine, by dissolving 2 g of dimethyl-p-aminobenzaldehyde in 100 ml of 5% hydrochloric acid and adding this reagent to urine; a red colour in the cold indicates the presence of an excessive amount of urobilinogen.
(05 Mar 2000)
Ehrlich's diazo reaction The reaction of diazotised sulfanilic acid with bilirubin to form azobilirubin, which forms the basis of quantitating the amount of bilirubin in biological fluids.
See: van den Bergh's test.
Synonym: Ehrlich's diazo reaction.
(05 Mar 2000)
Ehrlich's diazo reagent Two solutions, one of sodium nitrite, the other of acidified sulfanilic acid, used in bringing about diazotization.
Synonym: Ehrlich's diazo reagent.
(05 Mar 2000)
Ehrlich's inner body A round oxyphil body found in the red blood cell in case of haemocytolysis due to a specific blood poison.
Synonym: Heinz-Ehrlich body.
(05 Mar 2000)
Ehrlich's phenomenon The difference between the amount of diphtheria toxin that will exactly neutralise one unit of antitoxin and that which, added to one unit of antitoxin, will leave one lethal dose free is greater than one lethal dose of toxin; i.e., it is necessary to add more than one lethal dose of toxin to a neutral mixture of toxin and antitoxin to make the mixture lethal (the basis of the L+ dose).
(05 Mar 2000)
Ehrlich's postulate Ehrlich postulated that cells contained surface extensions or side chains (haptophores) that bind to the antigenic determinants of a toxin (toxophores); after a cell is stimulated, the haptophores are released into the circulation and become the antibodies.
See: receptor.
Synonym: Ehrlich's postulate.
(05 Mar 2000)
Ehrlich's theory Ehrlich postulated that cells contained surface extensions or side chains (haptophores) that bind to the antigenic determinants of a toxin (toxophores); after a cell is stimulated, the haptophores are released into the circulation and become the antibodies.
See: receptor.
Synonym: Ehrlich's postulate.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á